Valspodar(PSC833)
产品编号: DC9813
Featured
我们的合作伙伴:
中国地区超过5000个高品质化合物库存
应用领域
Valspodar是一种选择性的P-糖蛋白抑制剂，已被用作实验性癌症治疗和化学增敏剂。
| Cas No.: |
121584-18-7 |
| 名称: |
|
| 别名: |
PSC 833; PSC-833; PSC833 |
| SMILES: |
C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C |
| 分子式: |
C63H111N11O12 |
| 分子量: |
1214.62 |
| 纯度: |
|
| 保存条件: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: |
|
| In Vivo: |
|
| In Vitro: |
|
| References: |
Valspodar(PSC833) is a P-glycoprotein (P-gp) inhibitor widely used in preclinical and clinical studies for overcoming multidrug resistance (MDR). In rat, Valspodar showed properties of low hepatic extraction and wide distribution, similar to that of its structural analogue cyclosporine A. Administration of Valspodar to animals before mitoxantrone treatment increased the accumulation of mitoxantrone in the MDR tumors to 94% of that in the wild-type tumors. These studies have added direct in vitro and in vivo visual information on how P-gp processes anticancer compounds and how P-gp inhibitors modulate MDR in resistant cancer cells. |
| Kinase Assay: |
|
| Cell Assay: |
|
| Animal Administration: |
|
| References: |
|
MSDS
| TITLE |
DOWNLOAD |
| MSDS_2817_DC9813_121584-18-7 |
|
COA
| LOT NO. |
DOWNLOAD |
|
|
询盘
